BioScrip, Inc. (Nasdaq: BIOS) announced today that Teva Neuroscience tapped BioScrip Specialty Pharmacy as one of several national research study participants in one of the most comprehensive MS research studies announced to date.
TOP MS is a new research study for MS patients. The study will collect information, through online surveys about the quality of life, symptoms, relapse, employment, usual level of activity participation and general health activity from individuals living with MS for a two-year period.
“We are very pleased that BioScrip was selected as a specialty pharmacy study participant”, said Rick Smith, president and COO of BioScrip Inc.
“Teva recognized our BioscripCare™ MS program’s ability to provide high-quality, comprehensive and personalized MS care on a national basis. At BioScrip, we believe that this study will reaffirm our ongoing commitment to BioscripCare drug therapy adherence programs for patients and physician support services to improve the quality of life for the MS patient.”